BEI
ALNY icon

Benjamin Edwards Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Benjamin Edwards Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
1,168
+83
+8% +$25K ﹤0.01% 1168
2026
Q1 		$359K Buy
1,085
+352
+48% +$120K ﹤0.01% 1104
2025
Q4 		$291K Buy
733
+246
+51% +$109K ﹤0.01% 1128
2025
Q3 		$222K Buy
+487
New +$198K ﹤0.01% 1212

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Benjamin Edwards Inc's ALNY Position: Q2 2026 in Review

Benjamin Edwards Inc increased its Alnylam Pharmaceuticals (ALNY) stake by 7.6% in Q2 2026, buying an estimated $25K and bringing the position to 1,168 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Benjamin Edwards Inc first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $359K in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Benjamin Edwards Inc held 1,168 shares of Alnylam Pharmaceuticals worth $352K as of Q2 2026.
  • Benjamin Edwards Inc bought 83 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $25K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Benjamin Edwards Inc's portfolio in Q2 2026, its #1168 holding.
  • Benjamin Edwards Inc first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Benjamin Edwards Inc's Alnylam Pharmaceuticals position peaked at $359K in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.